.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Healthtrust
AstraZeneca
Teva
QuintilesIMS
Chubb
Cipla
UBS
Argus Health
Farmers Insurance

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,187,405

« Back to Dashboard

Which drugs does patent 9,187,405 protect, and when does it expire?


Patent 9,187,405 protects GILENYA and is included in one NDA. There has been one Paragraph IV challenge on Gilenya.

This patent has twenty-five patent family members in twelve countries.

Summary for Patent: 9,187,405

Title:S1P receptor modulators for treating relasping-remitting multiple sclerosis
Abstract: The present invention relates uses of an S1P receptor modulator such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula X ##STR00001## for the treatment or prevention of neo-angiogenesis associated with a demyelinating disease, e.g. multiple sclerosis.
Inventor(s): Hiestand; Peter C. (Austria, CH), Schnell; Christian (Hesingue, FR)
Assignee: Novartis AG (Basel, CH)
Application Number:14/257,342
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis
GILENYA
fingolimod
CAPSULE;ORAL022527-001Sep 21, 2010RXYesYes► Subscribe► Subscribe TREATMENT OF AUTOIMMUNE DISEASE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,187,405

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0612721.1Jun 27, 2006

Non-Orange Book Patents for Patent: 9,187,405

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,741,963S1P receptor modulators for treating multiple sclerosis► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,187,405

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2569732► Subscribe
Russian Federation2013131176► Subscribe
Mexico2008016133► Subscribe
South Korea20150122812► Subscribe
South Korea20140069178► Subscribe
South Korea20090024281► Subscribe
Japan2016185957► Subscribe
Japan2013166761► Subscribe
Japan2009541386► Subscribe
Hong Kong1214758► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Fish and Richardson
Citi
Covington
US Army
Daiichi Sankyo
Boehringer Ingelheim
Dow
Healthtrust
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot